mivocabtagene autoleucel

all catalysts(0)

nothing on the calendar yet

News(8)

• Weighing the risks of CAR T in autoimmune disease as Kyverna nears market
  Not a month after reports of three deaths in autoimmune trials for Novartis' CAR T cell therapy ignited a debate about the use of these treatments in nonfatal diseases, Kyverna Therapeutics reporte…
  biospace · 5h ago
• AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll
  Summit Therapeutics scores a $2 billion equity investment from AstraZeneca to support ivonescimab’s late-stage development; uniQure crashes after four-year data from its Huntington’s disease gene t…
  biospace · 4d ago
• Kyverna steps closer to FDA-first CAR T for an autoimmune condition with durability data
  Kyverna Therapeutics' miv-cel showed improved mobility and a favorable safety profile at one year in patients with stiff person syndrome, further derisking an upcoming FDA application, William Blai…
  biospace · 10d ago
• Kyverna ‘resetting conversation’ with 1-year miv-cel data as autoimmune CAR-T peers hit safety snags
  As two Big Pharma players in the autoimmune CAR-T space face unexpected safety setbacks, Kyverna Therapeutics is reporting long-term clinical data that showcase sustained efficacy alongside an unbl…
  fiercebiotech · 11d ago
• Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts
  Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management could help developers avoid future safety hazards.
  biopharma_dive · 1mo ago
• Kyverna taps ElevateBio to secure commercial supply of autoimmune CAR-T therapy
  ElevateBio will be the primary source of Kyverna’s autologous CAR-T cell therapy for anticipated U.S. and global launches in autoimmune indications.
  biospace · 2mo ago
• Roche drops TCE for lupus, but hasn’t given up on autoimmune cell therapies
  Roche may have scrapped work on a T-cell engager being evaluated for lupus, but the company’s head of pharma told Fierce that still has a strategy for developing cell therapies for autoimmune disea…
  fiercebiotech · 2mo ago
• How Kyverna rode CAR T’s autoimmune wave to the FDA’s door
  Poised to become the first company to achieve a regulatory filing for a cell therapy in autoimmune disease, Kyverna Therapeutics is building a pipeline-in-a-product to change the treatment paradigm.
  biospace · 2mo ago